Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

被引：8
|
作者：
Ravi, Praful [1 ]
Whelpley, Bridget [1 ]
Kelly, Emma [1 ]
Wolanski, Andrew [1 ,2 ]
Ritzer, Jolivette [1 ,2 ]
Robertson, Matthew [1 ,2 ]
Shah, Hina [1 ,2 ]
Morgans, Alicia K. [1 ]
Wei, Xiao X. [1 ]
Sunkara, Rajitha [1 ]
Pomerantz, Mark [1 ]
Taplin, Mary -Ellen [1 ]
Kilbridge, Kerry L. [1 ]
Choudhury, Atish D. [1 ]
Jacene, Heather [1 ,2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷 / 03期
关键词：
RESISTANT PROSTATE-CANCER; MULTICENTER; THERAPY;
D O I：
10.2967/jnumed.122.265194
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：349 / 350
页数：2
相关论文
共 45 条
  • [1] Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice
    Jadvar, Hossein
    Iravani, Amir
    Bodei, Lisa
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (12) : 1851 - 1854
  • [2] Radiation Dosimetry in 177Lu-PSMA-617 Therapy
    Jackson, Price
    Hofman, Michael
    McIntosh, Lachlan
    Buteau, James Patrick
    Kumar, Aravind Ravi
    SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (02) : 243 - 254
  • [3] A Hangover Under 177Lu-PSMA-617 Therapy
    Poterszman, Nathan
    Somme, Laura
    Bund, Caroline
    Hutt, Emilie
    Somme, Francois
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : 582 - 583
  • [4] Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
    Pathmanandavel, Sarennya
    Crumbaker, Megan
    Ho, Bao
    Yam, Andrew O.
    Wilson, Peter
    Niman, Remy
    Ayers, Maria
    Sharma, Shikha
    Hickey, Adam
    Eu, Peter
    Stockler, Martin
    Martin, Andrew J.
    Joshua, Anthony M.
    Nguyen, Andrew
    Emmett, Louise
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (02) : 221 - 226
  • [5] Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Kiess, Ana
    Lukens, J. Nicholas
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2025, 15 (01) : 14 - 18
  • [6] Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions
    Wang, Jingnan
    Zang, Jie
    Wang, Hao
    Liu, Qingxing
    Li, Fang
    Lin, Yansong
    Huo, Li
    Jacobson, Orit
    Niu, Gang
    Fan, Xinrong
    Zhu, Zhaohui
    Chen, Xiaoyuan
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 431 - 438
  • [7] Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617
    Kristiansson, Amanda
    Timmermand, Oskar Vilhelmsson
    Altai, Mohamed
    Strand, Joanna
    Strand, Sven-Erik
    Akerstrom, Bo
    Orbom, Anders
    PHARMACEUTICS, 2022, 14 (04)
  • [8] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [9] First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
    van Kalmthout, Ludwike
    Braat, Arthur
    Lam, Marnix
    van Leeuwaarde, Rachel
    Krijger, Gerard
    Ververs, Tessa
    Mehra, Niven
    Bins, Adriaan
    Hunting, Jarmo
    de Keizer, Bart
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 446 - 451
  • [10] First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
    Nulent, Thomas J. W. Klein
    van Es, Robert J. J.
    Willems, Stefan M.
    Braat, Arthur J. A. T.
    Devriese, Lot A.
    de Bree, Remco
    de Keizer, Bart
    EJNMMI RESEARCH, 2021, 11 (01)
12345